Menu
COVID-19
Federal Resources
State Resources
Telehealth
Legislative Updates
Take Action
Action Alerts
Legislator Search
How to be an Advocate
Policy Agenda
International Pricing Index
Access to Medicare Part B Therapies
Value-Based Reimbursement
Consolidation of Community Care
In-Office Dispensing
Value of Integrated Cancer Care
State Policy Map
Health Policy Reports
Contact Us
About the PAC
Login
Register
Login
/
Register
Recent News
AJMC: Clinical Pathways: Reducing Costs and Improving Quality Across a Network
MORNING CONSULT: Insurance Companies Have No Place Practicing Medicine
JAMA NETWORK: Adding Patient-Reported Outcomes to Medicare’s Oncology Value-Based Payment Model
JCO ONCOLOGY PRACTICE: De-Constructing the Proposed Radiation Oncology Model Payment Methodology: Implications for Practices and Opportunities for Improvement
AUSTIN AMERICAN-STATESMAN: Medicare Part B reforms put Texas cancer patients in the crosshairs
THE DAILY GAZETTE: Oppose changes to Medicare policies
INSIDE SOURCES: Drug Price Index Would Mean Higher Costs, Less Care for Patients
REAL CLEAR MARKETS: Cheap Pharmaceutical Costs by Federal Decree Is a Dangerous Path
FORBES: The Bizarre World of Drug Pricing
THE HILL: International price index for medicine will harm patients
SUN SENTINEL: Drug pricing is a deadly national scandal
THE MERCURY NEWS: Trump Medicare drug plan would hurt most vulnerable
THE COLORADOAN: New Medicare rules put cancer patients at risk
MORNING CONSULT: Physicians Have a Different Approach to Medicare Part B
NEW YORK TIMES: Trump Officials Say Drug Prices Are Inflated. So Are Some of Their Claims on a Solution.
WASHINGTON STATE WIRE: Proposed changes to Medicare Part B could be bad news for Washington Arthritis Patients
THE AMERICAN SPECTATOR: Part B Drug Reforms Do Not Put American Patients First
INVESTOR'S BUSINESS DAILY: Trump's Drug Pricing Scheme Will Hurt Seniors And Health Care Providers
CINCINNATI ENQUIRER: Patients struggle to access lifesaving cancer treatments
MORNING CONSULT: For Oncologists, Trump’s Medicare Part B Plan Makes Treating Cancer Harder
THE HILL: Drug pricing reforms will disrupt cancer care for millions
The US Oncology Network Comments on the International Pricing Index Model for Medicare Part B Drugs
The US Oncology Network Comments on Proposed Outpatient Prospective Payment Rule
The US Oncology Network Comments on Proposed Medicare Physician Fee Schedule and Quality Payment Program Rule
The Us Oncology Network Responds to RFI Regarding the Physician Self-Referral Law
The Network Responds to Health Care Innovation RFI on Value-Based Provider Payment Reform
The Network Submits Comments on the American Patients First Blueprint
The US Oncology Network Responds to RFI on Promoting Healthcare Choice and Competition
The Network Comments on Reducing Regulation and Controlling Regulatory Costs
The US Oncology Network Responds to the RFI on CMS’ Innovation Center New Direction
The US Oncology Network Comments on Proposed Medicare Physician Fee Schedule
The US Oncology Network Comments on Proposed Hospital Outpatient Payment System
The US Oncology Network Comments on Proposed Part B Drug Payment Model
Oncology Community Unites Against Potential CMS Part B Drug Payment Model
The US Oncology Network and ASP Coalition Partners Urge CMS to Withdraw Part B Drug Payment Model
The US Oncology Network Highlights Use of Clinical Pathways in Comments to Senate on Breakthrough Therapies
The US Oncology Network and Alliance Partners Urge Expansion of Site Neutral Payment Policies
The US Oncology Network Emphasizes Importance of In-Office Ancillary Services Exception in the Stark Law
